Apolipoprotein E3

• 

  Subject Areas on Research

  • A SAGE study of apolipoprotein E3/3, E3/4 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. 
  • A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. 
  • A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. 
  • A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy. 
  • APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. 
  • APOE genotype affects outcome in a murine model of sepsis: implications for a new treatment strategy. 
  • APOE genotype-specific differences in human and mouse macrophage nitric oxide production. 
  • APOE genotype-specific differences in the innate immune response. 
  • Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis. 
  • Altered immune responses in apolipoprotein E-deficient mice. 
  • An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction. 
  • Androgen-mediated immune function is altered by the apolipoprotein E gene. 
  • Apo E structure determines VLDL clearance and atherosclerosis risk in mice. 
  • ApoE genotype-specific inhibition of apoptosis. 
  • ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. 
  • ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. 
  • ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory. 
  • Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. 
  • Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. 
  • Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor. 
  • Apolipoprotein E controls the risk and age at onset of Parkinson disease. 
  • Apolipoprotein E gene polymorphisms and retinal vascular signs: the atherosclerosis risk in communities (ARIC) study. 
  • Apolipoprotein E gene polymorphisms are not associated with diabetic retinopathy: the atherosclerosis risk in communities study. 
  • Apolipoprotein E genotype and oxidative stress response to traumatic brain injury. 
  • Apolipoprotein E isoform mediated regulation of nitric oxide release. 
  • Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. 
  • Apolipoprotein E isotype-dependent modulation of microRNA-146a in plasma and brain. 
  • Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex. 
  • Apolipoprotein E uptake and low-density lipoprotein receptor-related protein expression by the NTera2/D1 cell line: a cell culture model of relevance for late-onset Alzheimer's disease. 
  • Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. 
  • Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. 
  • Apolipoprotein E-epsilon 4 frequency in geriatric depression. 
  • Apolipoprotein E-genotype dependent hippocampal and cortical responses to traumatic brain injury. 
  • Apolipoprotein E-low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner. 
  • Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes. 
  • Apolipoprotein E4 decreases whereas apolipoprotein E3 increases the level of secreted amyloid precursor protein after closed head injury. 
  • Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor. 
  • Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway. 
  • Apolipoprotein e gene and age-related maculopathy in older individuals: the cardiovascular health study. 
  • Association between APOE epsilon 2/epsilon 3/epsilon 4 polymorphism and disability severity in a national long-term care survey sample. 
  • Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. 
  • Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function. 
  • Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele. 
  • ERG responses and microarray analysis of gene expression in a multifactorial murine model of age-related retinal degeneration. 
  • Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production. 
  • Estradiol enhances long term potentiation in hippocampal slices from aged apoE4-TR mice. 
  • Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. 
  • High-fat/high-cholesterol diet promotes a S1P receptor-mediated antiapoptotic activity for VLDL. 
  • Hippocampal sulcal cavities on MRI: relationship to age and apolipoprotein E genotype. 
  • Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior. 
  • Human apoE3 but not apoE4 rescues impaired astrocyte activation in apoE null mice. 
  • Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. 
  • Human apolipoprotein E isoform-specific differences in neuronal sprouting in organotypic hippocampal culture. 
  • Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice. 
  • Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. 
  • Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. 
  • Human apolipoprotein E4 targeted replacement mice show increased prevalence of intracerebral hemorrhage associated with vascular amyloid deposition. 
  • Human apolipoprotein E4 worsens acute axonal pathology but not amyloid-β immunoreactivity after traumatic brain injury in 3xTG-AD mice. 
  • Identification of plasma biomarkers of TBI outcome using proteomic approaches in an APOE mouse model. 
  • Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion. 
  • Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischaemia. 
  • Inherited frailty. ApoE alleles determine survival after a diagnosis of heart disease or stroke at ages 85+. 
  • Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. 
  • Microglial function in human APOE3 and APOE4 transgenic mice: altered arginine transport. 
  • Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. 
  • Patterns of brain activation in people at risk for Alzheimer's disease. 
  • Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. 
  • Prefrontal activation patterns in subjects at risk for Alzheimer disease. 
  • Reversal of presynaptic deficits of apolipoprotein E-deficient mice in human apolipoprotein E transgenic mice. 
  • Rosiglitazone induces mitochondrial biogenesis in mouse brain. 
  • TOMM40'523 variant and cognitive decline in older persons with APOE ε3/3 genotype. 
  • Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. 
  • Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. 
  • The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype. 
  • The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. 
  • Uptake and internalization of exogenous apolipoprotein E3 by cultured human central nervous system neurons. 
  • Vascular smooth muscle actin is reduced in Alzheimer disease brain: a quantitative analysis. 
• 

  Keywords of People

  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Innovation & Entrepreneurship
  • Warner, David Samuel, Distinguished Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology